Cardiology Today -- ATLANTA – Patient with acute coronary syndromes who undergo CABG surgery are less likely to develop fatal outcomes when given ticagrelor, a reversible, more intense P2Y12 receptor antagonist, instead of clopidogrel as antiplatelet therapy, according to results of a subgroup analysis of the PLATO trial.
